CN111867579B - Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 - Google Patents

Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 Download PDF

Info

Publication number
CN111867579B
CN111867579B CN201980017463.XA CN201980017463A CN111867579B CN 111867579 B CN111867579 B CN 111867579B CN 201980017463 A CN201980017463 A CN 201980017463A CN 111867579 B CN111867579 B CN 111867579B
Authority
CN
China
Prior art keywords
ccr6
compound
antagonist
cells
cxcr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980017463.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111867579A (zh
Inventor
J·J·坎贝尔
K·埃伯斯华斯
A·卡拉辛斯基
V·R·马利
J·麦克马洪
R·辛格
杨菊
喻超
张朋烈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN111867579A publication Critical patent/CN111867579A/zh
Application granted granted Critical
Publication of CN111867579B publication Critical patent/CN111867579B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980017463.XA 2018-01-08 2019-01-07 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 Active CN111867579B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614927P 2018-01-08 2018-01-08
US62/614,927 2018-01-08
US201862715503P 2018-08-07 2018-08-07
US62/715,503 2018-08-07
PCT/US2019/012519 WO2019136370A2 (en) 2018-01-08 2019-01-07 Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2

Publications (2)

Publication Number Publication Date
CN111867579A CN111867579A (zh) 2020-10-30
CN111867579B true CN111867579B (zh) 2023-11-24

Family

ID=67140280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980017463.XA Active CN111867579B (zh) 2018-01-08 2019-01-07 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法

Country Status (9)

Country Link
US (2) US11207294B2 (https=)
EP (1) EP3737366B1 (https=)
JP (1) JP7322036B2 (https=)
CN (1) CN111867579B (https=)
AU (1) AU2019205786B2 (https=)
IL (1) IL275839B2 (https=)
MA (1) MA50424A (https=)
TW (1) TWI821235B (https=)
WO (1) WO2019136370A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
BR112022021976A2 (pt) 2020-04-30 2022-12-13 Idorsia Pharmaceuticals Ltd Composto, e, composição farmacêutica compreendendo um composto
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
EP4423082A1 (en) 2021-10-26 2024-09-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
KR20240090693A (ko) 2021-10-28 2024-06-21 이도르시아 파마슈티컬스 리미티드 Ccr6 수용체 조절인자

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087607A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
CA2049973C (en) 1990-02-28 2002-12-24 Rodney G. Wolff Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
MXPA02011868A (es) 2000-05-30 2003-04-10 Smithkline Beecham Corp Antagonistas de receptor de interleucina 8.
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
DE60230722D1 (de) 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
RU2003126913A (ru) 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
PL208928B1 (pl) 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
CN101514193B (zh) 2003-04-18 2012-12-19 默沙东公司 呋喃取代的二氧代环丁烯的合成
AU2005210504B2 (en) 2004-01-30 2009-01-08 Merck Sharp & Dohme Corp. Crystalline polymorphs of a CXC-chemokine receptor ligand
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
AR061829A1 (es) 2006-07-07 2008-09-24 Schering Corp Ciclobuten-1, 2-dionas 3,4-di sustituidas como ligandos de receptores de quimiocinas cxc
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
ES2386489T3 (es) 2007-06-06 2012-08-21 Novartis Ag Compuestos ciclobutanediona sustituidos anti-inflamatorios
WO2009005801A1 (en) 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009005802A1 (en) 2007-07-05 2009-01-08 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
US20100267712A1 (en) 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
RU2529468C2 (ru) 2008-06-24 2014-09-27 Топотаргет А/С Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2350067A2 (en) 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
HUE035751T2 (hu) 2011-09-02 2018-08-28 Novartis Ag Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
KR102038310B1 (ko) * 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
JP2015522546A (ja) 2012-05-23 2015-08-06 ステマージ バイオテクノロジー エスエー ミトコンドリア電子伝達鎖の複合体（ｉｉｉ）の活性の阻害剤およびその使用
WO2015170430A1 (ja) * 2014-05-08 2015-11-12 学校法人慶應義塾 大動脈解離後の炎症性障害抑制剤
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087607A1 (en) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulators of chemokine receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin;Alexander M. Foster等;《The Journal of Immunology》;20140418;第192卷(第12期);第6053-6061页 *

Also Published As

Publication number Publication date
CN111867579A (zh) 2020-10-30
IL275839B2 (en) 2024-02-01
US11684606B2 (en) 2023-06-27
US11207294B2 (en) 2021-12-28
EP3737366A2 (en) 2020-11-18
TWI821235B (zh) 2023-11-11
EP3737366B1 (en) 2026-02-25
JP2021510160A (ja) 2021-04-15
US20190209527A1 (en) 2019-07-11
EP3737366A4 (en) 2022-07-27
IL275839B1 (en) 2023-10-01
WO2019136370A3 (en) 2020-04-16
US20220280481A1 (en) 2022-09-08
WO2019136370A2 (en) 2019-07-11
IL275839A (en) 2020-08-31
AU2019205786A1 (en) 2020-08-06
EP3737366C0 (en) 2026-02-25
AU2019205786B2 (en) 2023-12-14
JP7322036B2 (ja) 2023-08-07
MA50424A (fr) 2020-08-26
CA3087701A1 (en) 2019-07-11
TW201936600A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
CN111867579B (zh) Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
Strong Rodrigues et al. Cutaneous graft-versus-host disease: diagnosis and treatment
Ritchlin et al. New therapies for psoriasis and psoriatic arthritis
EP2101780B1 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
KR20180102642A (ko) C3 사구체병증을 치료하는 방법
JP5834004B2 (ja) ループス治療のための方法および組成物
JP2007525465A (ja) 重症急性呼吸症候群（ｓａｒｓ）の治療のための、組成物および方法
JP2017031209A (ja) アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
Kanatoula et al. Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases
Qasem et al. Therapeutic advancements in the management of psoriasis: a clinical overview and update
KR20200108297A (ko) 세르둘라티닙-함유 국소 피부 약제학적 조성물 및 이의 용도
CN113453759A (zh) 治疗巨细胞动脉炎
EP3376869B1 (en) Treatment of autoimmune disease
Flowers Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months
CA3087701C (en) Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
JP2005529152A (ja) 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
CN119345364A (zh) 用tyk2抑制剂治疗脱发障碍的方法
CN118103069A (zh) 治疗中度至重度特应性皮炎的方法
Ryan et al. Recent and future developments in targeted therapy
CA2577883A1 (en) Tnf-binding protein-1 in the treatment of psoriasis
Alckseev Platform Session VI: Large Trials—Acute

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant